Armistice Capital’s 13F Filings Document Concentrated Institutional Activity in Specialty Pharma
Armistice Capital appears in the 13F filings of multiple specialty pharmaceutical companies, reflecting a portfolio strategy concentrated on drug developers with active regulatory pipelines across rare diseases, neurological conditions, and cardiovascular medicine. The fund manages more than $7 billion in assets and ranks among the more active healthcare-focused hedge funds tracked in institutional holdings databases. […]